

## Synthesis, Characterization and Biological Screening of Quinoline Linked Oxadiazole Derivatives as Potent Antibacterial Agents

Jayesh P. Jadhav<sup>1\*</sup>, Kokila A. Parmar<sup>1</sup>, Shailesh C. Kotval<sup>1</sup>, Tessy John<sup>1</sup>, Vikaskumar R. Shukla<sup>1</sup>, Margi A. Patel<sup>1</sup> and Bijal M. Patel<sup>1</sup>

<sup>1</sup> Department of Chemistry, Hemchandracharya North Gujarat University, Patan, Gujarat -384265, INDIA

\*Correspondence: E-mail: [jayesh\\_591@yahoo.com](mailto:jayesh_591@yahoo.com)

DOI: <http://dx.doi.org/10.33980/jbcc.2019.v05i01.0012>

(Received 26 Feb, 2019; Accepted 01 Apr, 2019; Published 06 Apr, 2019)

**ABSTRACT:** A series of ten derivatives of quinolin-8-yl[(5-aryl-1,3,4-oxadiazol-2-yl)sulfanyl]acetate was designed and derived through various steps. The structures of synthesized compounds were determined by IR, <sup>1</sup>H NMR and Mass spectroscopy analyses. The antibacterial strength of synthesized compounds was evaluated by using bacterial strains *Staphylococcus aureus*, *Bacillus subtilis*, *Pseudomonas aeruginosa* and *Escherichia coli* where the study data reveals that some of the compounds have good antibacterial potential.

**Keywords:** Quinoline; oxadiazole; acetamide and biological evaluation.

**INTRODUCTION:** Heterocyclic chemistry is an integral part of organic chemistry which covers more than half of the literature with numbers of novel heterocyclic compounds with different hetero atomic nucleus. The presence of nitrogen and oxygen heteroatom in five-member ring generates an important heterocyclic nucleus known as oxadiazole. This oxadiazole nucleus has diverse biological applications as antimicrobial<sup>1-5</sup>, antioxidant<sup>6-9</sup>, anticancer<sup>10-12</sup>, anti-inflammatory<sup>13</sup>, analgesic<sup>14</sup>, anti-tubercular<sup>15 & 16</sup>, anti-convulsant<sup>17-18</sup>, Alzheimer<sup>19</sup>, anti-allergic<sup>20</sup> etc. In this work, we have generated series of compounds linked with 1,3,4-oxadiazole nucleus having antibacterial potential.

**MATERIAL AND METHODS:** In the preparation of derivatives laboratory and analytical grade chemicals were selected. The melting points of derivatives were measured by open capillary method and are uncorrected. To check the purity of compounds TLC method was elected where silica gel coated aluminum plates (Merk) were used with appropriate mobile phase and obtaining spots were visualized in UV chamber. The Perkin-Elmer 237 spectrophotometer instrument was used where IR spectra was recorded by KBr pellet, Mass spectra was recorded on MS route JMS 600-H instrument and Bruker AM -400 instrument was used to record NMR spectra using DMSO as solvent and TMS as internal standards.

**General Procedure for preparation of quinolin-8-yl[(5-aryl-1,3,4-oxadiazol-2-yl)sulfanyl]acetate:**

**Step I: Synthesis of aryl enoate (2)** - In this step, various substituted aromatic acid (0.1 mol) and concentrated H<sub>2</sub>SO<sub>4</sub> (6.0 ml) were taken in methanol (80 ml) and refluxed for 12 to 14 hours. The resulting reaction mass was then poured into crushed ice, stirred well and products were separated from reaction mass. The purification of products was carried out in ethyl alcohol. A mixture of toluene: acetone (8:2) was used as eluent to check the progress of reaction by TLC method.

**Step II: Synthesis of aryl hydrazide (3)** - In the synthesis of various substituted benzohydrazide, the mixture of aryl enoate (0.1 mol) and hydrazine hydrate (0.2 mol) were taken in methyl alcohol (80 ml) and refluxed for 12 to 15 hours. The reaction mass was then cooled, poured into crushed ice, stirred well and products were isolated from reaction mass. The products were recrystallized by ethyl alcohol. The progress of reaction was monitored by TLC method with toluene: acetone (8:2) as eluent.

**Step III: Synthesis of 5-aryl-1,3,4-oxadiazole-2-thiol (4)** - To synthesize 5-aryl-1,3,4-oxadiazole-2-thiol, the mixture of aryl hydrazide (0.1 mol), CS<sub>2</sub> (0.1 mol) and alcoholic KOH (0.05 mol) were refluxed in methyl alcohol (80 ml) for 12 to 15 hours. The resulting mass was poured into crushed ice and 2N HCl was used to


neutralize the mass. The mass was then filtered and washed by cold water to isolate the products. The products were recrystallized by ethyl alcohol. The progress of reaction was monitored by TLC using toluene: acetone (8:2) as eluent.

**Step IV: Synthesis of quinolin-8-yl chloroacetate (7)**  
 -The mixture of chloro acetyl chloride (0.1 mol), 2-4 drops of TEA and quiniol-8-ol (0.1 mol) in toluene (70 ml) was refluxed for 06 hours. The product was collected from the reaction mass by separation technique and washed by toluene (25 ml). The purification of product was done by ethyl alcohol. A TLC method

was used to check the progress of reaction using toluene: acetone (8:2) as eluent.

**Step V: Synthesis of quinolin-8-yl [(5-aryl-1,3,4-oxadiazol-2-yl)sulfanyl]acetate (8)**  
 -The mixture of 5-aryl-1,3,4-oxadiazole-2-thiol (0.1 mol), quinolin-8-yl chloroacetate (0.1 mol), anhydrous  $K_2CO_3$  (0.2 mol) were taken in dry acetone (50 ml) and stirred for 05 hours. The reaction mixture was then poured into crushed ice, stirred well, filtered and washed by cold water. The products were recrystallized by ethyl alcohol. The progress of reaction was monitored by TLC using toluene: acetone (8:2) as eluent.

[Reaction Scheme]



[Where; R = a) 2-Br, b) 4-F, c) 3,4,5-OCH<sub>3</sub>, d) 4-NO<sub>2</sub>, e) 4-Br, f) 2-Cl, g) 4-CH<sub>3</sub>, h) 2-NO<sub>2</sub>, i) 4-Cl, j) 2-CH<sub>3</sub>]

**RESULTS AND DISCUSSION:****Characterization:**

**8(a). Quinolin-8-yl [[5-(2-bromophenyl)-1,3,4-oxadiazol-2-yl]sulfanyl]acetate:** Yield 56%, m.p. 170-172° C, FT-IR (KBr): 659 (C-Br), 1141 (C-O-C), 1469 (-C=C-), 1568 (-C=N), 1769 (-C=O), 2916 (-CH<sub>2</sub>-), <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>): 4.54 (s, 2H, -CH<sub>2</sub>-), δ 7.21-7.25 (s, 2H, Ar-H), δ 7.35-7.39 (m, 2H, Ar-H), δ 7.46-7.47 (m, 1H, Ar-H), 7.63-7.65 (m, 1H, Ar-H), δ 7.91-7.95 (s, 2H, Ar-H), δ 7.99-8.01 (m, 1H, Ar-H), δ 8.39-8.41 (m, 1H, Ar-H), MS : m/z 443, Anal. Calcd for C<sub>19</sub>H<sub>12</sub>BrN<sub>3</sub>O<sub>3</sub>S: C-51.60, H-2.73, N-9.50, S-7.25 Anal. Found C-51.57, H-2.69, N-9.48, S-7.21%.

**8(b). Quinolin-8-yl [[5-(4-fluorophenyl)-1,3,4-oxadiazol-2-yl]sulfanyl]acetate:** Yield 68%, m.p. 161-163° C, FT-IR (KBr): 1138 (C-O-C), 1374 (C-F), 1465 (-C=C-), 1595 (-C=N), 1764(-C=O), 2935 (-CH<sub>2</sub>-), <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>): 4.77 (s, 2H, -CH<sub>2</sub>-), δ 7.44-7.48 (s, 2H, Ar-H), δ 7.55-7.59 (m, 2H, Ar-H), δ 7.65-7.66 (m, 1H, Ar-H), 7.93-7.95 (m, 1H, Ar-H), δ 8.05-8.09 (s, 2H, Ar-H), δ 8.43-8.45 (m, 1H, Ar-H), δ 8.76-8.77 (m, 1H, Ar-H), MS : m/z 382, Anal. Calcd for C<sub>19</sub>H<sub>12</sub>FN<sub>3</sub>O<sub>3</sub>S: C-59.84, H-3.17, N-11.02, S-8.41 Anal. Found C-59.83, H-3.16, N-11.01, S-8.39%.

**8(c). Quinolin-8-yl [[5-(3,4,5-trimethoxyphenyl)-1,3,4-oxadiazol-2-yl]sulfanyl]acetate:** Yield 76%, m.p. 182-184° C, FT-IR (KBr): 1084 (C-O-C alkanyl), 1157 (C-O-C), 1473 (-C=C-), 1588 (-C=N), 1779(-C=O), 2921 (-CH<sub>2</sub>-), <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>): δ 3.49 (s, 6H, -OCH<sub>3</sub>), δ 3.56 (s, 3H, -OCH<sub>3</sub>) 4.53 (s, 2H, -CH<sub>2</sub>-), δ 7.19-7.23 (s, 2H, Ar-H), δ 7.43-7.47 (m, 2H, Ar-H), δ 7.59-7.61 (m, 1H, Ar-H), 7.88-7.90 (m, 1H, Ar-H), δ 8.13-8.15 (s, 2H, Ar-H), δ 8.39-8.41 (m, 1H, Ar-H), δ 8.62-8.64 (m, 1H, Ar-H), MS : m/z 455, Anal. Calcd for C<sub>22</sub>H<sub>19</sub>N<sub>3</sub>O<sub>6</sub>S: C-58.27, H-4.22, N-9.27, S-7.07 Anal. Found C-58.24, H-4.19, N-9.24, S-7.04%.

**8(d). Quinolin-8-yl [[5-(4-nitrophenyl)-1,3,4-oxadiazol-2-yl]sulfanyl]acetate:** Yield 69%, m.p. 177-179° C, FT-IR (KBr): 1163 (C-O-C), 1482 (-C=C-), 1601 (-C=N), 1786(-C=O), 2898 (-CH<sub>2</sub>-), <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>): δ 4.37 (s, 2H, -CH<sub>2</sub>-), δ 7.22-7.26 (s, 2H, Ar-H), δ 7.49-7.53(m, 2H, Ar-H), δ 7.64-7.68 (m, 1H, Ar-H), 7.93-7.97 (m, 1H, Ar-H), δ 8.19-8.21 (s, 2H, Ar-H), δ 8.45-8.47 (m, 1H, Ar-H), δ 8.69-8.71 (m, 1H, Ar-H), MS : m/z 409, Anal. Calcd for C<sub>19</sub>H<sub>12</sub>N<sub>4</sub>O<sub>5</sub>S: C-55.88, H-2.96, N-13.72, S-7.85 Anal. Found C-55.86, H-2.94, N-13.68, S-7.83%.

**8(e). Quinolin-8-yl [[5-(4-bromophenyl)-1,3,4-oxadiazol-2-yl]sulfanyl]acetate:** Yield 69%, m.p. 183-185° C, FT-IR (KBr): 673(C-Br), 1157 (C-O-C), 1469 (-C=C-), 1608 (-C=N), 1698 (-C=O), 2893 (-CH<sub>2</sub>-), <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>): 4.47 (s, 2H, -CH<sub>2</sub>-), δ 7.13-7.17 (s, 2H, Ar-H), δ 7.32-7.36 (m, 2H, Ar-H), δ 7.48-7.50 (m, 1H, Ar-H), 7.67-7.69 (m, 1H, Ar-H), δ 7.99-8.01 (s, 2H, Ar-H), δ 8.12-8.14 (m, 1H, Ar-H), δ 8.45-8.47 (m, 1H, Ar-H), MS : m/z 443, Anal. Calcd for C<sub>19</sub>H<sub>12</sub>BrN<sub>3</sub>O<sub>3</sub>S: C-51.60, H-2.73, N-9.50, S-7.25 Anal. Found C-51.59, H-2.71, N-9.46, S-7.22%.

**8(f). Quinolin-8-yl [[5-(2-chlorophenyl)-1,3,4-oxadiazol-2-yl]sulfanyl]acetate:** Yield 64%, m.p. 170-172° C, FT-IR (KBr): 659 (C-Cl), 1160 (C-O-C), 1463 (-C=C-), 1598 (-C=N), 1776 (-C=O), 2903 (-CH<sub>2</sub>-), <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>): 4.38 (s, 2H, -CH<sub>2</sub>-), δ 7.12-7.16 (s, 2H, Ar-H), δ 7.29-7.33 (m, 2H, Ar-H), δ 7.51-7.53 (m, 1H, Ar-H), 7.69-7.71 (m, 1H, Ar-H), δ 7.86-7.90 (s, 2H, Ar-H), δ 7.96-7.98 (m, 1H, Ar-H), δ 8.22-8.24 (m, 1H, Ar-H), MS : m/z 398, Anal. Calcd for C<sub>19</sub>H<sub>12</sub>ClN<sub>3</sub>O<sub>3</sub>S: C-57.36, H-3.04, N-10.56, S-8.06 Anal. Found C-57.33, H-3.01, N-10.52, S-8.02%.

**8(g). Quinolin-8-yl [[5-(4-methylphenyl)-1,3,4-oxadiazol-2-yl]sulfanyl]acetate:** Yield 73%, m.p. 176-178° C, FT-IR (KBr): 1182 (C-O-C), 1479 (-C=C-), 1609 (-C=N), 1798 (-C=O), 2872 (-CH<sub>2</sub>-), <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>): δ 2.41 (s, 3H, -CH<sub>3</sub>), δ 4.60 (s, 2H, -CH<sub>2</sub>-), δ 7.04-7.08 (s, 2H, Ar-H), δ 7.23-7.27 (m, 2H, Ar-H), δ 7.57-7.59 (m, 1H, Ar-H), 7.73-7.76 (m, 1H, Ar-H), δ 7.89-7.93 (s, 2H, Ar-H), δ 8.04-8.06 (m, 1H, Ar-H), δ 8.43-8.45 (m, 1H, Ar-H), MS : m/z 378, Anal. Calcd for C<sub>20</sub>H<sub>15</sub>N<sub>3</sub>O<sub>3</sub>S: C-63.65, H-4.01, N-11.13, S-8.49 Anal. Found C-63.63, H-3.99, N-11.12, S-8.47%.

**8(h). Quinolin-8-yl [[5-(2-nitrophenyl)-1,3,4-oxadiazol-2-yl]sulfanyl]acetate:** Yield 59%, m.p. 157-159° C, FT-IR (KBr): 1149 (C-O-C), 1456 (-C=C-), 1586 (-C=N), 1768 (-C=O), 2893 (-CH<sub>2</sub>-), <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>): 4.26 (s, 2H, -CH<sub>2</sub>-), δ 7.18-7.22 (s, 2H, Ar-H), δ 7.33-7.37 (m, 2H, Ar-H), δ 7.56-7.58 (m, 1H, Ar-H), 7.67-7.71 (m, 1H, Ar-H), δ 7.82-7.86 (s, 2H, Ar-H), δ 7.99-8.03(m, 1H, Ar-H), δ 8.32-8.36 (m, 1H, Ar-H), MS : m/z 409, Anal. Calcd for C<sub>19</sub>H<sub>12</sub>N<sub>4</sub>O<sub>5</sub>S: C-55.88, H-2.96, N-13.72, S-7.85 Anal. Found C-55.85, H-2.92, N-13.71, S-7.81%.

**8(i). Quinolin-8-yl [[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]sulfanyl]acetate:** Yield 72%, m.p. 181-183° C, FT-IR (KBr): 659 (C-Cl), 1178 (C-O-C), 1474 (-C=C-), 1583 (-C=N), 1772 (-C=O), 2843 (-CH<sub>2</sub>-), <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>): 4.27 (s, 2H, -

CH<sub>2</sub>-),  $\delta$  7.15-7.19 (s, 2H, Ar-H),  $\delta$  7.31-7.35 (m, 2H, Ar-H),  $\delta$  7.54-7.55 (m, 1H, Ar-H),  $\delta$  7.67-7.69 (m, 1H, Ar-H),  $\delta$  7.93-7.97 (s, 2H, Ar-H),  $\delta$  8.13-8.15 (m, 1H, Ar-H),  $\delta$  8.47-8.49 (m, 1H, Ar-H), MS : m/z 398, Anal. Calcd for C<sub>19</sub>H<sub>12</sub>ClN<sub>3</sub>O<sub>3</sub>S: C-57.36, H-3.04, N-10.56, S-8.06 Anal. Found C-57.35, H-3.03, N-10.53, S-8.04%.

8(j). *Quinolin-8-yl* *[[5-(2-methylphenyl)-1,3,4-oxadiazol-2-yl]sulfanyl]acetate*: Yield 58%, m.p. 164-166° C, FT-IR (KBr): 1196 (C-O-C), 1484 (-C=C-), 1602 (-C=N), 1787 (-C=O), 2891 (-CH<sub>2</sub>-), <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  2.37 (s, 3H, -CH<sub>3</sub>),  $\delta$  4.51 (s, 2H, -CH<sub>2</sub>-),  $\delta$  7.11-7.15 (s, 2H, Ar-H),  $\delta$  7.29-7.33 (m, 2H, Ar-H),  $\delta$  7.59-7.61 (m, 1H, Ar-H),  $\delta$  7.70-7.72 (m, 1H, Ar-H),  $\delta$  7.91-7.95 (s, 2H, Ar-H),  $\delta$  8.11-8.13 (m, 1H, Ar-H),  $\delta$  8.34-8.38 (m, 1H, Ar-H),

MS : m/z 378, Anal. Calcd for C<sub>20</sub>H<sub>15</sub>N<sub>3</sub>O<sub>3</sub>S: C-63.65, H-4.01, N-11.13, S-8.49 Anal. Found C-63.61, H-3.97, N-11.10, S-8.45%.

**Biological study:** The antibacterial study of synthesized compounds was determined by efficient disc diffusion technique using *Staphylococcus aureus*, *Bacillus subtilis*, *Pseudomonas aeruginosa* and *Escherichia coli* bacterial strains in which DMSO was selected as solvent and nutrient agar as culture media. The study was carried out at different concentration and zone of inhibition was measured after 24 hours of incubation at 37° C. The effective antibacterial agent streptomycin was selected as reference in this study and the antibacterial data of synthesized compounds are mentioned in the following table.

Table 1: Antibacterial data of synthesized compounds.

Comp. Code	Gram Positive Bacteria				Gram Negative Bacteria			
	<i>Staphylococcus aureus</i>		<i>Bacillus subtilis</i>		<i>Pseudomonas aeruginosa</i>		<i>E. coli</i>	
	Zone of Inhibition (mm)	MIC (µg/ml)	Zone of Inhibition (mm)	MIC (µg/ml)	Zone of Inhibition (mm)	MIC (µg/ml)	Zone of Inhibition (mm)	MIC (µg/ml)
8a	9	>12.5	5	12.5	6	25	7	12.5
8b	8	12.5	11	>12.5	8	12.5	8	12.5
8c	8	25	16	50	8	25	7	25
8d	16	12.5	19	12.5	--	12.5	18	50
8e	8	12.5	--	--	8	12.5	31	100
8f	8	12.5	5	12.5	7	50	12	50
8g	13	25	9	12.5	16	12.5	14	12.5
8h	15	50	14	25	18	100	--	--
8i	10	>12.5	8	12.5	7	12.5	9	>12.5
8j	15	50	12	12.5	16	12.5	19	100
Refer- ence drug	12	>12.5	13	>12.5	16	>12.5	13	>12.5

The antibacterial study data reveals that compounds 8a, 8b, 8f and 8i found to possess excellent antibacterial potential against all bacterial strains used for study compared to reference compound while rest of the compounds show moderate and poor activity. In this study compounds 8d, 8e and 8h found inactive against different bacterial strains.

**CONCLUSION:** The synthesized derivatives were prepared through various steps and different spectroscopy analyses support the structures of synthesized compounds. The biological potential of synthesized compounds was evaluated as potent antibacterial compounds.

## REFERENCES:

- Chennapragada K. P. and Palagummi V. S. (2018) Synthesis and Characterization of 2-phenyl-5-(1-phenyl-3-(3, 4, 5-trimethoxyphenyl)-1H-pyrazo-4-yl)-1, 3, 4-oxadiazole Scaffolds for Assessing Their Medicinal Potentials, *Indian Journal of Pharmaceutical Education and Research*, 52(1), 135-45.
- Farshori N. N., Rauf A., Siddiqui M. A., Al-Sheddi E. S. and Al-Oqail M. M. (2017) A facile one-pot synthesis of novel 2, 5-disubstituted-1, 3, 4-oxadiazoles under conventional and microwave conditions and evaluation of their in vitro antimicro-

- crobial activities, *Arabian Journal of Chemistry*, 1, S2853-61.
3. Ceylan S. (2016) Synthesis and biological evaluation of new Mannich and Schiff bases containing 1, 2, 4-triazole and 1, 3, 4-oxadiazole nucleus, *Medicinal Chemistry Research*, 25(9), 1958-70.
  4. Ghoneim A. A. and Mohamed, S. A. (2013), Synthesis and Antimicrobial activity of Some 1, 3, 4-Oxadiazoles-2-thione and 1, 2, 4-Triazoles Derivatives from Tert-Butyl Carbazate, *Oriental Journal of Chemistry*, 29(2), 525-31.
  5. Arif, A., Abbasi, M. A., Siddiqui, S. Z., Rasool, S. and Shah, S. A. (2017) Synthesis and pharmacological screening: Sulfa derivatives of 2-pipecoline-bearing 1, 3, 4-oxadiazole core, *Russian Journal of Bioorganic Chemistry*, 43(3), 328-39.
  6. Mihailović N., Marković V., Matić I. Z., Stanisavljević N. S., Jovanović Ž. S., Trifunović S. and Joksović L. (2017), Synthesis and antioxidant activity of 1, 3, 4-oxadiazoles and their diacylhydrazine precursors derived from phenolic acids, *RSC Advances*, 7(14), 8550-60.
  7. Rabie A. M., Tantawy A. S. and Badr S. M. (2016) Design, Synthesis, and Biological Evaluation of Novel 5-Substituted-2-(3, 4, 5-trihydroxyphenyl)-1, 3, 4-oxadiazoles as Potent Antioxidants, *American Journal of Organic Chemistry*, 6(2), 54-80.
  8. Patrao P., Khader A. M. and Kalluraya B. (2013) Synthesis of new 5-naphthyl substituted 1, 3, 4-oxadiazole derivatives and their antioxidant activity, *Der Pharm Chem*, 5, 24-32.
  9. Ranganatha V. L. and Khanum S. A. (2014), Synthesis and evaluation of in vitro antioxidant properties of novel 2, 5-disubstituted 1, 3, 4-oxadiazoles, *Russian Journal of Bioorganic Chemistry*, 40(2), 206-13.
  10. Özdemir A., Sever B., Altıntop M. D., Temel H. E., Atlı Ö., Baysal M. and Demirci F. (2017) Synthesis and Evaluation of New Oxadiazole, Thiazole, and Triazole Derivatives as Potential Anticancer Agents Targeting MMP-9, *Molecules*, 22(7), 1109.
  11. Siddiqui T., Alam M. G. and Dar A. M. (2015) Synthesis, characterization and anticancer studies of new steroidal oxadiazole, pyrrole and pyrazole derivatives, *Journal of Saudi Chemical Society*, 19(4), 387-91.
  12. Murty M. S., Rao B. R., Katiki M. R., Nath L. R. and Anto R. J. (2013) Synthesis of piperazinyl benzothiazole/benzoxazole derivatives coupled with 1, 3, 4-oxadiazole-2-thiol: novel hybrid heterocycles as anticancer agents, *Medicinal Chemistry Research*, 22(10), 4980-91.
  13. Iyer V. B., Gurupadayya B., Koganti V. S., Inturi B. and Chandan R. S. (2017) Design, synthesis and biological evaluation of 1, 3, 4-oxadiazoles as promising anti-inflammatory agents, *Medicinal Chemistry Research*, 26(1), 190-204.
  14. Viveka S., Shama P., Nagaraja G. K., Deepa N. and Sreenivasa M. Y. (2016) Design, synthesis, and pharmacological studies of some new Mannich bases and S-alkylated analogs of pyrazole integrated 1, 3, 4-oxadiazole, *Research on Chemical Intermediates*, 42(3), 2597-617.
  15. Desai N. C., Trivedi A. R., Vaghani H. V., Somani H. C. and Bhatt K. A. (2016) Synthesis and biological evaluation of 1, 3, 4-oxadiazole bearing dihydropyrimidines as potential antitubercular agents, *Medicinal Chemistry Research*, 25(2), 329-38.
  16. Ladani G. G. and Patel M. P. (2015) Novel 1, 3, 4-oxadiazole motifs bearing a quinoline nucleus: synthesis, characterization and biological evaluation of their antimicrobial, antitubercular, antimalarial and cytotoxic activities, *New Journal of Chemistry*, 39(12), 9848-57.
  17. Shaharyar M., Mazumder A., Garg R. and Pandey R. D. (2016) Synthesis, characterization and pharmacological screening of novel benzimidazole derivatives, *Arabian Journal of Chemistry*, 9, S342-7.
  18. Kumudha D., Kalavathi T. and Venkatanarayanan R. (2014) Synthesis and evaluation of pharmacological activities of some 1, 3, 4-oxadiazoles, 1, 2, 4-triazoles possessing s-triazole moiety, *World J Pharm Res*, 3, 526-37.
  19. Rehman A. U., Nafeesa K., Abbasi M. A., Siddiqui S. Z., Rasool S., Shah S. A. and Ashraf M. (2018) Synthesis of new heterocyclic 3-piperidinyl-1, 3, 4-oxadiazole derivatives as potential drug candidate for the treatment of Alzheimer's disease, *Cogent Chemistry*, 4(1), 1472197.
  20. Guda D. R., Park S. J., Lee M. W., Kim T. J. and Lee M. E. (2013) Syntheses and anti-allergic activity of 2-((bis(trimethylsilyl)methylthio)methylsulfonyl)methyl)-5-aryl-1, 3, 4-oxadiazoles, *European journal of medicinal chemistry*, 62, 84-88.